Company Filing History:
1 out of 50 
1 out of 192 
1 out of 1 Years Active: 2013-2014
Title: Patrizia Castellani: Innovator in Monoclonal Antibody Research
Introduction
Patrizia Castellani is a prominent inventor based in Genoa, Italy. She has made significant contributions to the field of monoclonal antibodies, focusing on their applications in cancer diagnosis and therapy. With a total of 2 patents, her work has the potential to impact the medical community significantly.
Latest Patents
Her latest patents include groundbreaking inventions. The first patent is titled "Monoclonal antibody and its use for the identification of the oncofetal isoform of fibronectin (B-FN) for diagnosis or therapy." This invention describes epitopes localized on FNIII-repeat that are normally cryptic but are unmasked by the insertion of FNIII-B into the FN molecule. The patent also details antibodies or their fragments that can identify the aforementioned epitope.
The second patent, "Selective targeting of tumor vasculature using antibody molecules," relates to selectively targeting tumoral vasculature in vivo. This is achieved using a human recombinant scFv, L19, which targets the angiogenesis marker ED-B domain of fibronectin. The invention explores various antibody formats, including a complete human IgG1 and a mini-immunoglobulin, for different diagnostic and therapeutic purposes.
Career Highlights
Throughout her career, Castellani has worked with notable companies such as Philogen S.p.a. and Bayer Schering Pharma AG. Her experience in these organizations has allowed her to develop her innovative ideas further and contribute to advancements in medical research.
Collaborations
Some of her coworkers include Laura Borsi and Enrica Balza, who have collaborated with her on various projects. Their teamwork has been instrumental in driving forward the research and development of her patented technologies.
Conclusion
Patrizia Castellani is a distinguished inventor whose work in monoclonal antibodies is paving the way for new diagnostic and therapeutic approaches in oncology. Her contributions are vital to the ongoing advancements in medical science.